(Q79080321)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel (English)

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

14 March 2024

1 reference

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

14 March 2024

author name string

Brian Leyland-Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Karen Gelmon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Jean-Pierre Ayoub

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Andrew Arnold

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Shail Verma

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Reg Dias

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Parviz Ghahramani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

language of work or name

English

0 references

publication date

24 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 December 2019

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.12.109

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Journal of Clinical Oncology

14 March 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

3965-3971

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

19 December 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

14 March 2024

2

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Humanization of an anti-p185HER2 antibody for human cancer therapy

14 March 2024

4

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

14 March 2024

6

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

14 March 2024

7

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

14 March 2024

8

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

14 March 2024

9

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Dose scheduling--Herceptin

14 March 2024

10

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

14 March 2024

11

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

14 March 2024

14

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

14 March 2024

15

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

14 March 2024

21

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

14 March 2024

23

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

14 March 2024

24

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

14 March 2024

25

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom

14 March 2024

26

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.12.109

14 March 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14507946%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference